循环胰岛素样生长因子与阿尔茨海默病:一项孟德尔随机化研究
本研究采用孟德尔随机化设计,利用IGAP汇总数据(17,008例病例、37,154例对照)及瑞典双胞胎注册库独立样本(984例病例、10,304例对照),检验遗传预测的循环IGF1及IGFBP3变异是否与阿尔茨海默病风险相关。Meta分析未提示IGF1、IGFBP3或其摩尔比变异影响AD风险;仅FOXO3基因一个SNP与AD风险相关,合并后每风险等位基因OR为1.04(95%CI 1.01-1.08;p=0.008)。结论认为循环IGF1和IGFBP3并非AD风险的重要决定因素,FOXO3可能通过独立于IGF信号的通路影响AD。
要点
- 遗传预测的循环IGF1、IGFBP3及其摩尔比变异与AD风险无显著关联。
- FOXO3基因变异与AD风险轻度相关,合并OR为1.04(95%CI 1.01-1.08;p=0.008)。
- FOXO3对AD的影响可能不依赖IGF信号通路。
核心结论
- 循环IGF1和IGFBP3不是阿尔茨海默病风险的重要决定因素。
- FOXO3功能可能通过独立于IGF信号的多效性通路影响AD发生。
研究设计与样本
- 孟德尔随机化研究,首先利用IGAP已发表全基因组关联汇总数据(17,008例病例、37,154例对照)分析9个IGF相关SNP与AD风险的关联。
- 随后在瑞典双胞胎注册库独立样本(984例病例、10,304例对照)中评估SNP-疾病结果的重复性。
主要发现
- SNP-AD结果的Meta分析未提示IGF1、IGFBP3或其摩尔比的变异影响AD风险。
- IGAP数据中仅一个SNP似乎影响AD风险,该变异位于与人类长寿相关的FOXO3基因。
- 合并IGAP与次要数据的Meta分析中,每FOXO3风险等位基因的AD OR为1.04(95%CI 1.01-1.08;p=0.008)。
临床怎么用
- 临床不宜将循环IGF1或IGFBP3作为AD风险评估的遗传或生物标志物依据。
- FOXO3相关通路可能为AD机制研究提供独立于IGF信号的探索方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine whether genetically predicted variation in circulating insulin-like growth factor 1 (IGF1) or its binding protein, IGFBP3, are associated with risk of Alzheimer disease (AD), using a mendelian randomization study design. METHODS: We first examined disease risk by genotypes of 9 insulin-like growth factor (IGF)-related single nucleotide polymorphisms (SNPs) using published summary genome-wide association statistics from the International Genomics of Alzheimer's Project (IGAP; n = 17,008 cases; 37,154 controls). We then assessed whether any SNP-disease results replicated in an independent sample derived from the Swedish Twin Registry (n = 984 cases; 10,304 controls). RESULTS: Meta-analyses of SNP-AD results did not suggest that variation in IGF1, IGFBP3, or the molar ratio of these affect AD risk. Only one SNP appeared to affect AD risk in IGAP data. This variant is located in the gene FOXO3, implicated in human longevity. In a meta-analysis of both IGAP and secondary data, the odds ratio of AD per FOXO3 risk allele was 1.04 (95% confidence interval 1.01-1.08; p = 0.008). CONCLUSIONS: These findings suggest that circulating IGF1 and IGFBP3 are not important determinants of AD risk. FOXO3 function may influence AD development via pathways that are independent of IGF signaling (i.e., pleiotropic actions).
引用
- Williams DM, Karlsson IK, Pedersen NL, et al. Circulating insulin-like growth factors and Alzheimer disease: A mendelian randomization study. Neurology. 2017. PMID: 29282328. doi:10.1212/WNL.0000000000004854
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。